Randomized trial or adjuvant tamoxifen pour years vs two years in node positive breast cancer women.

被引：0

作者：

Gallén, M ^{[1
]}

Alonso, C ^{[1
]}

Ojeda, B ^{[1
]}

Viladíu, P ^{[1
]}

Beltrán, W ^{[1
]}

Borrás, J ^{[1
]}

Tusquets, I ^{[1
]}

Arcusa, A ^{[1
]}

Barnadas, A ^{[1
]}

Bastús, R ^{[1
]}

Balil, A ^{[1
]}

Batiste-Alentorn, E ^{[1
]}

Guasch, I ^{[1
]}

Garau, I ^{[1
]}

Boleda, W ^{[1
]}

Badia, A ^{[1
]}

机构：

[1] Hosp Del Mar, Barcelona, Spain

来源：

EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S56 / S56

页数：1

共 50 条

[21] Tamoxifen (T) vs tamoxifen plus uracil-ptegafur (T+UFT) in the adjuvant treatment of postmenopausal women with node positive breast cancer
Iglesias, L
Gomez, A
Moreno, A
Montano, A
Ruiz, M
Calvo, E
Pastor, P
Noguer, M
Barea, JL
Noguei, JAM
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S207 - S207
[22] Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer
Heidemann, E
STRAHLENTHERAPIE UND ONKOLOGIE, 1998, 174 (05) : 290 - 291
[23] Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
Saarto, T
Blomqvist, C
Ehnholm, C
Taskinen, MR
Elomaa, I
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 429 - 433
[24] RANDOMIZED TRIAL TO EVALUATE THE ADDITION OF TAMOXIFEN TO CYCLOPHOSPHAMIDE, 5-FLUOROURACIL, PREDNISONE ADJUVANT THERAPY IN PREMENOPAUSAL WOMEN WITH NODE-POSITIVE BREAST-CANCER
INGLE, JN
EVERSON, LK
WIEAND, HS
CULLINAN, SA
WOLD, LE
HAGEN, JB
MARTIN, JK
KROOK, JE
FITZGIBBONS, RG
FOLEY, JF
AHMANN, DL
PFEIFLE, DM
GREEN, SJ
CANCER, 1989, 63 (07) : 1257 - 1264
[25] Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
Nordenskjold, Anna
Fohlin, Helena
Rosell, Johan
Bengtsson, Nils-Olof
Fornander, Tommy
Hatschek, Thomas
Lindman, Henrik
Malmstrom, Per
Ryden, Lisa
Wallgren, Arne
Stal, Olle
Nordenskjold, Bo
BREAST, 2023, 71 : 63 - 68
[26] CARDIAC AND VASCULAR MORBIDITY IN WOMEN RECEIVING ADJUVANT TAMOXIFEN FOR BREAST-CANCER IN A RANDOMIZED TRIAL
MCDONALD, CC
ALEXANDER, FE
WHYTE, BW
FORREST, AP
STEWART, HJ
BRITISH MEDICAL JOURNAL, 1995, 311 (7011): : 977 - 980
[27] Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age
Carsten Rose
Claus Kamby
Henning T. Mouridsen
Michael Andersson
Lars Bastholt
Knud Aage Møller
Jørn Andersen
Pia Munkholm
Per Dombernowsky
Ib Jarle Christensen
Breast Cancer Research and Treatment, 2000, 61 : 103 - 110
[28] Updated results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group for Cancer Care Evaluation study of adjuvant treatment in breast cancer 01 (SITAM 01).
Valentini, M
Belfiglio, M
Pellegrini, F
Sacco, M
Nicolucci, A
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 10S - 10S
[29] Adjuvant CMF improves outcome of node negative breast cancer (BC) in premenopausal women: In years results of a randomized study
Espie, M
Mignot, L
Leleu, F
DeRoquancourt, A
Maylin, C
Morvan, F
Clot, P
Marty, M
EUROPEAN JOURNAL OF CANCER, 1997, 33 : 349 - 349
[30] ADJUVANT RANDOMIZED TRIALS OF DOXORUBICIN CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN CYCLOPHOSPHAMIDE TAMOXIFEN AND CMF CHEMOTHERAPY VERSUS TAMOXIFEN IN WOMEN WITH NODE-POSITIVE BREAST-CANCER
KAUFMANN, M
JONAT, W
ABEL, U
HILFRICH, J
CAFFIER, H
KREIENBERG, R
TRAMS, G
BRUNNERT, K
SCHERMANN, J
KLEINE, W
MAHLKE, M
NEISES, M
STOSIEK, U
STIGLMAYER, R
SEEGER, F
LANGNICKEL, D
NAGEL, G
GAMPE, M
MAASS, H
KUBLI, F
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 454 - 460

← 1 2 3 4 5 →